This study aims to conduct a two-stage GWAS for disease-free survival (DFS) in breast cancer stratified by tumor subtypes defined by the ER, PR, and HER2 status and evaluate the performance of prognostic models that included genetic variants with well-known clinical factors. Here, PGR is linked to breast carcinoma.